Indivior PLC (NASDAQ:INDV) Receives $39.33 Consensus Price Target from Analysts

Shares of Indivior PLC (NASDAQ:INDV) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $39.3333.

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Finally, HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th.

Insider Activity at Indivior

In other news, Director David E. Wheadon purchased 1,771 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $62,675.69. Following the completion of the acquisition, the director directly owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. This trade represents a 14.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark Stejbach acquired 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 4,871 shares of company stock worth $172,385 in the last 90 days.

Hedge Funds Weigh In On Indivior

A number of large investors have recently modified their holdings of the business. Oaktree Capital Management LP boosted its stake in shares of Indivior by 2,241.6% in the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after buying an additional 246,776,273 shares in the last quarter. Divisadero Street Capital Management LP boosted its position in shares of Indivior by 2,372.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after purchasing an additional 3,226,605 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares in the last quarter. Goldentree Asset Management LP acquired a new position in shares of Indivior during the 3rd quarter worth $42,630,000. Finally, Newtyn Management LLC increased its holdings in shares of Indivior by 61.1% in the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after purchasing an additional 1,592,982 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Price Performance

Shares of Indivior stock opened at $33.86 on Friday. The firm’s fifty day simple moving average is $34.96 and its 200-day simple moving average is $28.78. Indivior has a 12 month low of $7.62 and a 12 month high of $38.00. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of 36.80 and a beta of 0.80.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.